Piezo Motion, Benson Engineering Join Forces to Provide OEMs with Breakthrough Technology
Piezo Motion partners with Benson Engineering to deliver affordable micro-precision motors and motion control solutions to the Southern U.S.
LAKEWOOD RANCH, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- via InvestorWire – Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and Benson Engineering today announce a partnership. Piezo Motion is a developer and leading manufacturer of automation technology. Benson Engineering, founded in 1946, is a family-owned manufacture representative group with offices in Texas and Missouri.
Benson Engineering works primarily with original equipment manufacturers (OEMs) in Texas, Louisiana, Oklahoma, Arkansas, Kansas, Missouri, Nebraska and Iowa. Piezo Motion’s multifaceted rotary and linear motors are built with technology that provides a stable, accurate motor that is designed specifically for OEMs that require ultimate speed, size and accuracy.
"We are looking forward to sharing the outstanding Piezo Motion platform with our customer and prospect base, expanding our value proposition with these clients who enjoy and look for next-level upgrades in motion technology,” said Alan Hobbs, vice president at Benson Engineering.
Piezo Motion motors are used globally for a variety of applications. These include laboratory instruments, biomedicine, optics, semiconductors, nanotechnology industries, and industrial electronic and automotive systems, along with an expanding portfolio of products that combine performance with dramatically lower cost over conventional piezo solutions.
“Our unique, tiny motors provide unparalleled precision and energy efficiencies to the market,” said Hassan Kotob, chairman and CEO of Brain Scientific. “Benson Engineering has been in the industry for more than 75 years and has a stellar reputation. We are looking forward to working with them and providing our precision motors to their customer base at an affordable price.”
About Piezo Motion
Piezo Motion (piezomotion.com), a Brain Scientific company, is a leader in precision motor technology with multimillion-dollar investments in research and development of affordable piezoelectric motors to meet, and exceed, the needs of today's global markets. The company is committed to the development of innovative technology and motion products that enhance functionality in a multitude of applications. The company works with startups, OEMs, research institutions and industrial companies from around the world, empowering the visionaries behind their products.
About Brain Scientific
Brain Scientific (brainscientific.com) is a medical technology company with multiple patents and FDA-cleared products. Brain Scientific is committed to developing next-gen solutions that advance the future of neurodiagnostic and OEM medical devices. Brain Scientific has two product lines covering neurology and precision motion. The NeuroCap and NeuroEEG are smart neurological diagnostic devices that simplify administration, shorten scan time, and cut costs. The Piezo Motion product line consists of ultra-efficient compact precision motors that will drive the next generation of medical devices. To learn more about Brain Scientific's corporate strategy, products, or investor relations, please visit brainscientific.com.
About Benson Engineering
Benson Engineering (bensonengineering.com) is a third-generation, family-owned, manufacture representative group founded in 1946. For more than 75 years, the company has strived to bring its customers quality products, outstanding service, and ethical standards beyond expectation. Benson Engineering’s personnel have all been with the company for a minimum of 20 years each giving long-standing expertise and experience in the territory with many OEMs and distributors.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items; (iii) the company's future financial performance; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, over many of which the company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the company's inability to obtain additional financing; the significant length of time and resources associated with the development of products and related insufficient cash flows and resulting illiquidity; the company's inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the company's raw materials; and the failure to implement the company's business plans or strategies. Some of these and other factors are identified and described in more detail in the company's filings with the SEC. The company does not undertake to update these forward-looking statements.
Released March 10, 2022